GlassScriptPhysician profile
Gurpreet Kaur
NPI 1528483658
$3,158.28
in general payments reported to CMS, 2019-2025
25 companies · $888 in 2025
The $888 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $545 · 2022: $503 · 2023: $538 · 2024: $683 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.37 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $510.53 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $359.35 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $304.10 | 2021-2025 | |
| Genzyme Corporation | $298.12 | 2021-2025 | |
| Abbvie INC. | $252.61 | 2022-2025 | |
| Amgen INC. | $247.77 | 2021-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $247.24 | 2021-2025 | Siliq, Duobrii, Cabtreo |
| Sun Pharmaceutical Industries INC. | $178.78 | 2021-2025 | Odomzo, Blu-U |
| Almirall LLC | $161.99 | 2021-2024 | Klisyri |
| Galderma Laboratories, L.P. | $72.31 | 2025 | Nemluvio |
| Pfizer INC. | $62.62 | 2021-2024 | |
| Leo Pharma INC. | $56.94 | 2021-2022 | |
| Botanix Sb INC | $53.02 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $47.73 | 2023-2025 | Dupixent |
| Paratek Pharmaceuticals, INC. | $41.89 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $40.36 | 2021-2022 | |
| Genentech USA, INC. | $38.18 | 2024 | Actemra, Erivedge |
| Dermavant Sciences, INC. | $35.16 | 2024 | Vtama |
| Astellas Pharma US INC | $24.27 | 2025 | Veozah |
| Lnhc, INC | $23.65 | 2025 | Zelsuvmi |
| Lilly USA, LLC | $22.84 | 2025 | Ebglyss |
| Organon LLC | $21.63 | 2025 | |
| Sebela Pharmaceuticals INC. | $19.94 | 2022 | |
| Verrica Pharmaceuticals INC. | $19.05 | 2023 | Ycanth |
| Biofrontera INC. | $18.20 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurpreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.